Replies to post #186999 on Biotech Values

[DewDiligence]

What about BMY's BTD for Daclatasvir + asunaprevir + BMS-791325? I assume it will be rescinded as well.

It may be moot insofar as BMY made no statement about submitting an NDA for this 3-DAA regimen on its 4Q14 CC.